BACKGROUND: Cardiac injury is common in severe coronavirus disease 2019 (COVID-19)
and is associated with poor outcomes. We aimed to study predictors of in-hospital death, …

Background Empagliflozin (EMPA) reduces heart failure hospitalization and mortality. The
benefit in terms of ventricular arrhythmia and contractility has not been explored. Objective To …

Objectives The aim of this study was to investigate the effects of rivaroxaban on left ventricle
thromboprophylaxis in patients with anterior ST-segment elevation myocardial infarction (…

Background: Left ventricular thrombus (LVT) can complicate ST-Elevation myocardial
infarction (STEMI) and is associated with poor outcomes. Conventional triple anticoagulation […

BACKGROUND Amlodipine has been shown to improve vascular endothelial function in
hypertensive patients, but whether S(-)-amlodipine has a similar effect remains controversial. …

Background Doxorubicin (Dox) is a potent chemotherapeutic agent, but its usage is limited by
dose-dependent cardiotoxicity. Intracellular calcium dysregulation has been reported to be …

Objective. To compare the difference of inflammatory cytokines and lymphocyte subsets
between deceased patients and survivors with COVID-19. Methods. This retrospective study …

Background Loeffler endocarditis is a relatively rare and potentially life-threatening heart
disease. This study aimed to identify the characteristic features of Loeffler endocarditis with …

Background: The role of rivaroxaban in patients with heart failure (HF) combined with left
ventricular (LV) thrombus remains unknown in current guideline-directed anticoagulant therapy…

Left ventricular pseudoaneurysm is an uncommon complication after transmural acute
myocardial infarction (AMI). Here we describe the case of a 43-year-old man who presented with …